INVA
Innoviva, Inc.
INVA's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over INVA overall, supported by stronger fundamentals and stronger valuation.
INVA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
INVA's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
INVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.1x | $11.47 | -40% |
| Fair | 6.8x | $15.21 | -20% |
| Current | 8.5x | $18.97 | — |
| Forward | 9.3x | $18.97 | — |
| Expensive | 20x | $44.09 | +132% |
Historical ranges are pointers, not guarantees.
INVA has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
INVA Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for INVA, with profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over INVA on the outlook, with more favorable valuation and profitability expectations.
INVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | -9.4% |
| Q3 2026 | $2.24 | +45% |
| Q2 2026 | $4.35 | +806% |
| Q1 2026 | $6.26 | +$7.10 |
| Q4 2025 | $3.30 | +817% |
| Q3 2025 | $1.54 | +117% |
| Q2 2025 | $0.48 | -71% |
| Q1 2025 | -$0.84 | -138% |
| Q4 2024 | $0.36 | -84% |
INVA earned $2.24 per share over the past year, up 45% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over INVA on earnings, with more consistent year-over-year improvement.
INVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $114.6M | +25% |
| Q4 2024 | $91.8M | +7% |
| Q4 2023 | $85.8M | +30% |
| Q3 2021 | $97.9M | +10% |
| Q2 2021 | $100.8M | +28% |
| Q1 2021 | $85.5M | +8.7% |
| Q4 2020 | $90.5M | +19% |
LLY has the stronger quarterly revenue trend. Revenue is up 17% for INVA versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 34% | +7.1 points |
| Q4 2024 | 27% | -44 points |
| Q4 2023 | 71% | +170 points |
| Q4 2022 | -98% | N/A |
| Q3 2021 | 97% | +1.4 points |
| Q2 2021 | 96% | -0.2 points |
| Q1 2021 | 93% | -3.8 points |
| Q4 2020 | 94% | -3.2 points |
INVA's operating margin was 34% last quarter, down 63 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
INVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $51.5M | +17% |
| Q1 2026 | $34.8M | -28% |
| Q4 2025 | $54.5M | -8% |
| Q2 2025 | $44.1M | +0.8% |
| Q1 2025 | $48.6M | +31% |
| Q4 2024 | $59.2M | +79% |
| Q3 2024 | $48.4M | +11% |
| Q2 2024 | $43.7M | +14% |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with INVA at down 21%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
INVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.8% | -1.4M shares |
| 1 year | -15% | -12.9M shares |
| 3 years | +10% | +6.6M shares |
| 5 years | -37% | -41.5M shares |
INVA has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $26.1M |
| Q2 2026 | $31.1M |
| Q1 2026 | $20.2M |
| Q4 2025 | $4.5M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
INVA spent $82M buying back its own shares over the past year, after none the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
INVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | 0.4x | Very low |
| Q2 2022 | 0.7x | Very low |
| Q1 2022 | 0.8x | Very low |
| Q4 2021 | 0.5x | Very low |
| Q3 2021 | 0.7x | Very low |
| Q2 2021 | 1.0x | Very low |
| Q1 2021 | 0.3x | Very low |
| Q4 2020 | 0.4x | Very low |
INVA's net debt is less than a year of its operating earnings (EBITDA).
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
INVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 22.2 | Neutral |
INVA's weekly RSI is 36 (neutral) and its Stochastic is 22 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
INVA PE vs Healthcare Sector
| Metric | INVA | Sector median | Relative |
|---|---|---|---|
| PE | 8.5x | 26x | 67% below |
| PE % | 68 | 29 | 39 pts above |
INVA has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
INVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 7% below |
| 20 week MA | $20.9 | 9.4% below |
| 50 week MA | $21.5 | 12% below |
| 100 week MA | $20.2 | 6.1% below |
| 200 week MA | $17.6 | 7.5% above |
INVA has fallen below most of its moving averages, though it's still 7.5% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over INVA on trend strength, trading above more of its moving averages.
INVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.3 | $12.3 | -13% |
| 2021 | $12.3 | $17.6 | +43% |
| 2022 | $17.6 | $13.2 | -25% |
| 2023 | $13.2 | $16.0 | +21% |
| 2024 | $16.0 | $17.6 | +9.4% |
| 2025 | $17.6 | $19.8 | +13% |
| 2026 YTD | $19.8 | $19.0 | -4.2% |
INVA has finished higher in four of the last six years. It's down 4.2% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over INVA on returns for 2026, with the stronger performance.